Background: Adherence to antipsychotic treatment is essential in treating schizophrenia symptoms and in preventing costly relapse. This study aimed to compare medication adherence and discontinuation in patients with schizophrenia treated with aripiprazole once-monthly long-acting injectable antipsychotic (LAI; AOM 400) to those who changed to a different oral antipsychotic. Methods: This retrospective cohort analysis used the Truven Health Analytics MarketScan® Medicaid, commercial, and supplemental Medicare claims databases. In patients ≥18 years old with schizophrenia, two mutually exclusive cohorts were created: the AOM 400 cohort, patients who initiated AOM 400 between 01/01/2013-06/30/2015 (the ID period); and the oral cohort, patients who changed to a different oral antipsychotic during the ID period. AOM 400 or new oral therapy initiation was the index date. Patients were followed for ≥1 year. Primary outcome measures were adherence (proportion of days covered [PDC]) during 1-year postindex and index medication discontinuation (gap ≥60 days) during entire follow-up. Cox regression and linear regression models were used to estimate risk of discontinuation and PDC, respectively, adjusting for demographic and clinical characteristics, insurance type, baseline medication, and baseline ED visits or hospitalizations. Results: The study sample consisted of 408 (10.8%) AOM 400 patients and 3,361 (89.2%) oral antipsychotic patients. AOM 400 patients had better medication adherence (adjusted mean PDC: 57.0% vs. 47.6%, p<0.001) than the oral cohort. Sixty-three percent of AOM 400 patients were partially (PDC 40%-79%) to fully adherent (PDC >80%) vs. 51.1% of oral antipsychotic patients (p<0.001). AOM 400 patients also had a lower medication discontinuation rate (75.2% vs. 85.0%; p<0.001) within 1 year. Median time to discontinuation of AOM 400 was 193 days vs. 89 days for oral antipsychotics (p<0.001). In the Cox model, oral antipsychotic patients discontinued their index treatment at a higher rate than AOM 400 patients (hazard ratio: 1.45; p<0.001). Discussion: This real-world study suggests that patients with schizophrenia initiating AOM 400 had better medication adherence and lower discontinuation risk than patients who changed to different oral antipsychotics.
Background: Childhood trauma has been proposed as a risk factor for schizophrenia. Moreover, it has been related to brain abnormalities associated with cognitive functions, including social cognition. Alterations in mentalizing skills are found in both schizophrenia patients and individuals exposed to childhood trauma. We hypothesize that childhood trauma might be related to emotional processing deficits in psychotic patients.
Methods:
The present study is ongoing. To date, we have assessed social cognition and childhood trauma in 30 patients with schizophrenia. Social cognition is quantified using Mayer, Salovey and Caruso emotional intelligence test (MSCEIT) with five different categories: i) emotional perception, ii) emotional facilitation, iii) emotional comprehension, iii) emotional management and iv) emotional intellectual quotient dimensions. Early trauma data is collected using Childhood Trauma Questionnaire (CTQ), which yields physical, emotional, sexual abuse and neglect scores. We have assessed the correlation coefficients (Spearman´s rho) between childhood trauma and social cognition scores. Results: According to our preliminary analyses, there are significant inverse correlation coefficients in the patients group between emotional neglect and total trauma scores and, on the other hand, social cognition scores for the facilitation, comprehension, management and emotional intellectual quotient dimensions. Thus, patients with higher scores reflecting more severe emotional neglect and total trauma performed lower in social cognition tests. Background: Deficits in social cognition often develop during the prodromal stages of psychosis, remain stable over the course of the illness, and have a dramatic impact on daily functioning (Fett et al., 2011) . Social cue processing, particularly face perception, plays a critical role in social cognitive functioning. Patients with schizophrenia struggle to extract information from faces and interpret facial expressions (Kohler et al., 2010) . These deficits may be explained by restricted visual attention. Indeed, eye-tracking studies have demonstrated that people with schizophrenia show reduced exploratory behaviour (i.e. reduced number of fixations and longer fixation durations) in response to facial stimuli compared to healthy controls (e.g. Manor et al., 1999) . Oxytocin has been demonstrated to exert pro-social effects on behaviour and modulate eye gaze during perception of faces. In the present study, we tested whether the neuropeptide, oxytocin, has a compensatory effect on visual processing of human faces. Methods: Twenty right-handed male subjects with schizophrenia (n = 16) or schizoaffective disorder (n = 4) were administered intranasal oxytocin 40UI or placebo in a double-blind, placebo-controlled, crossover fashion during two visits separated by 7 days. Participants engaged in a free-viewing eye-tracking task, during which they were looking at 6 facial images of two Caucasian men displaying angry, happy, and neutral facial expressions, and 6 control images in a random order. Eyetracking measures including 1) total number of fixations, 2) dispersion, 3) saccade amplitude, and 4) mean duration of fixations were captured using the EyeLink 1000 system (SR Research Ltd, Ottawa, Ontario, Canada). Four separate 2 x 4 repeated-measures analysis of variance (ANOVA) were carried out to evaluate the within-subject effects of treatment, stimuli, and the interactions between stimuli and treatment (p < .05, two-tailed). Results: We found a main effect of treatment (F1,17 = 16.139, p = .001), but not a main effect of stimuli (F3,51 = 1.479, p > .231) on total number of fixations. There was a main effect of treatment on duration of fixation, (F1,13 = 5.455, p = .036) but not a main effect of stimuli (F3,39 = 1.267, p = .299). For dispersion, there was a significant main effect of stimuli (F3,51 = 3.424, p = .024) but no main effect of treatment (F1,17 = 3.170, p = .093). Analysis of saccade amplitudes revealed no main effect of treatment (F1,17 = 2.666, p = .121) or stimuli (F3,51 = 0.289, p = .833). None of the interactions reached significance. Discussion: To our knowledge, this is the first study to explore the effects of oxytocin on eye movements in individuals with schizophrenia. We found that oxytocin increased exploratory viewing behaviour in response to affective facial stimuli by significantly increasing the total number and duration of fixations compared to placebo. While previous findings regarding oxytocin have been inconsistent, our findings are in line with research showing that the intranasal administration of 40UI oxytocin may improve social cognitive deficits in schizophrenia (e.g. Davis et al., 2013) . Future experiments may wish to explore the correlation between eye movement changes induced by oxytocin and facial affect recognition in larger samples.
